DURHAM, NC – Tranzyme Inc., a clinical-stage biotech firm based in Durham, has filed for a $75 million initial public offering of stock. Tranzyme plans to use the IPO dollars to boost advancement of its lead product. Founded in 1998, they will likely list on the NASDAQ with the symbol TZYM. In a market that has seen IPO’s all but disappear, this is an incredible step for Tranzyme and the North Carolina entrepreneurial community. Congratulations Tranzyme for this accomplishment!
Tranzyme is a long-time CED member and supporter. Company CEO and President, Vipin Garg, a current member of CED’s board of directors, frequently lends his expertise to the development and implementation of CED’s biotech and life science events. As recently as last week, Garg spoke at CED’s Direct Connections, an informal networking lunch program. In 2008, he was chairman of CED’s Biotech conference steering committee.
If you would like to know more, read the TechJournal South article below:
http://www.techjournalsouth.com/2010/11/durham-nc-based-tranzyme-files-for-75m-ipo/
No comments:
Post a Comment